238 related articles for article (PubMed ID: 10901376)
1. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies.
Harrington KJ; Rowlinson-Busza G; Syrigos KN; Uster PS; Abra RM; Stewart JS
Br J Cancer; 2000 Jul; 83(2):232-8. PubMed ID: 10901376
[TBL] [Abstract][Full Text] [Related]
2. Influence of tumour size on uptake of(111)ln-DTPA-labelled pegylated liposomes in a human tumour xenograft model.
Harrington KJ; Rowlinson-Busza G; Syrigos KN; Abra RM; Uster PS; Peters AM; Stewart JS
Br J Cancer; 2000 Sep; 83(5):684-8. PubMed ID: 10944612
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery.
Harrington KJ; Rowlinson-Busza G; Syrigos KN; Uster PS; Vile RG; Stewart JS
Clin Cancer Res; 2000 Jun; 6(6):2528-37. PubMed ID: 10873109
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
[TBL] [Abstract][Full Text] [Related]
5. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.
Harrington KJ; Mohammadtaghi S; Uster PS; Glass D; Peters AM; Vile RG; Stewart JS
Clin Cancer Res; 2001 Feb; 7(2):243-54. PubMed ID: 11234875
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution and pharmacokinetics of 111In-dTPA-labelled pegylated liposomes after intraperitoneal injection.
Syrigos KN; Vile RG; Peters AM; Harrington KJ
Acta Oncol; 2003; 42(2):147-53. PubMed ID: 12801133
[TBL] [Abstract][Full Text] [Related]
7. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterisation of 111In-DTPA-trastuzumab.
Lub-de Hooge MN; Kosterink JG; Perik PJ; Nijnuis H; Tran L; Bart J; Suurmeijer AJ; de Jong S; Jager PL; de Vries EG
Br J Pharmacol; 2004 Sep; 143(1):99-106. PubMed ID: 15289297
[TBL] [Abstract][Full Text] [Related]
10. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
11. Single-fraction irradiation has no effect on uptake of radiolabeled pegylated liposomes in a tumor xenograft model.
Harrington KJ; Rowlinson-Busza G; Uster PS; Vile RG; Peters AM; Stewart JS
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1141-8. PubMed ID: 11240257
[TBL] [Abstract][Full Text] [Related]
12. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
13. Doubly radiolabeled liposomes for pretargeted radioimmunotherapy.
Mougin-Degraef M; Bourdeau C; Jestin E; Saï-Maurel C; Bourgeois M; Saëc PR; Thédrez P; Gestin JF; Barbet J; Faivre-Chauvet A
Int J Pharm; 2007 Nov; 344(1-2):110-7. PubMed ID: 17592745
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals.
Helbok A; Decristoforo C; Dobrozemsky G; Rangger C; Diederen E; Stark B; Prassl R; von Guggenberg E
J Liposome Res; 2010 Sep; 20(3):219-27. PubMed ID: 19863193
[TBL] [Abstract][Full Text] [Related]
15. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
16. The effect of irradiation on the biodistribution of radiolabeled pegylated liposomes.
Harrington KJ; Rowlinson-Busza G; Syrigos KN; Uster PS; Vile RG; Peters AM; Stewart JS
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):809-20. PubMed ID: 11395251
[TBL] [Abstract][Full Text] [Related]
17. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
18. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model.
Harrington KJ; Rowlinson-Busza G; Syrigos KN; Vile RG; Uster PS; Peters AM; Stewart JS
Clin Cancer Res; 2000 Dec; 6(12):4939-49. PubMed ID: 11156255
[TBL] [Abstract][Full Text] [Related]
19. The effect of chelating agents on the distribution of monoclonal antibodies in mice.
Ward MC; Roberts KR; Westwood JH; Coombes RC; McCready VR
J Nucl Med; 1986 Nov; 27(11):1746-50. PubMed ID: 3464701
[TBL] [Abstract][Full Text] [Related]
20. Intraoperative therapy with liposomal drug delivery: retention and distribution in human head and neck squamous cell carcinoma xenograft model.
Wang SX; Bao A; Phillips WT; Goins B; Herrera SJ; Santoyo C; Miller FR; Otto RA
Int J Pharm; 2009 May; 373(1-2):156-64. PubMed ID: 19429301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
